Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi SA    SAN   FR0000120578

SANOFI SA

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : Regeneron See Positive Results From Dupixent Phase 3 Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2020 | 05:19pm EDT

By Kimberly Chin

 

Sanofi SA and Regeneron Pharmaceuticals Inc. said it had positive results for an advanced trial of a treatment for patients with a chronic, allergic inflammatory disease of the esophagus.

The Phase 3 trial of Dupixent met both its co-primary endpoints, as well as important secondary endpoints, the companies said. The trial had 81 patients, ages 12 years and older, who had eosinophilic esophagitis.

The patients were able to show clinical and anatomic improvements, including the ability to swallow. Patients saw a 69% reduction in disease symptoms, as well as a 60% reduction in their esophageal eosinophilic count to a normal range, the companies said.

Eosinophilic esophagitis damages the esophagus and impairs its functions, making it difficult to swallow. It could also damage and scar the esophagus without treatment.

This was the first and only biologic to show "positive and clinically meaningful results" in an advanced trial, the companies said.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS -1.65% 602.44 Delayed Quote.63.21%
SANOFI SA 1.33% 88.69 Real-time Quote.-2.33%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI SA
09:41aREGENERON PHARMACEUTICALS : Completes secondary offering of common stock held by..
AQ
09:41aREGENERON PHARMACEUTICALS : - libtayo longer-term results in advanced cutaneous ..
AQ
08:58aGLOBAL MARKETS LIVE: Target, Walmart, Sanofi…
01:57aSANOFI : Closes $11.7 Billion Sale of Regeneron Stake
DJ
05/29Sanofi announces closing of Regeneron stock sale
GL
05/29TAKE FIVE : Hong Kong takes centre stage
RE
05/29SANOFI : 's Board of Directors notes the resignation of Emmanuel Babeau and coop..
AQ
05/29Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous..
GL
05/29SANOFI : head of vaccines leaves for smaller competitor Ipsen
RE
05/29SANOFI : Names Four New Executive Committee Members
DJ
More news
Financials
Sales 2020 37 448 M 41 664 M 41 664 M
Net income 2020 5 741 M 6 387 M 6 387 M
Net Debt 2020 16 154 M 17 973 M 17 973 M
P/E ratio 2020 18,1x
Yield 2020 3,67%
Capitalization 110 B 122 B 122 B
EV / Sales 2019
EV / Sales 2020 3,36x
Nbr of Employees 100 409
Free-Float 89,1%
Chart SANOFI SA
Duration : Period :
Sanofi SA Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI SA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 104,08 €
Last Close Price 87,53 €
Spread / Highest target 40,3%
Spread / Average Target 18,9%
Spread / Lowest Target -2,89%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Chief Medical & Digital Officer
John C. Reed EVP & Global Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI SA-2.33%121 900
JOHNSON & JOHNSON1.97%391 896
ROCHE HOLDING AG5.96%295 228
PFIZER, INC.-2.53%212 139
MERCK & CO., INC.-11.25%203 745
NOVARTIS AG-9.65%190 274